Prudential Financial Inc. lifted its position in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 407.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 90,550 shares of the medical research company’s stock after acquiring an additional 72,720 shares during the quarter. Prudential Financial Inc. owned approximately 0.20% of Enzo Biochem worth $1,000,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in ENZ. Teachers Advisors LLC raised its position in shares of Enzo Biochem by 60.7% during the fourth quarter. Teachers Advisors LLC now owns 112,023 shares of the medical research company’s stock worth $777,000 after acquiring an additional 42,302 shares during the last quarter. Nationwide Fund Advisors raised its position in shares of Enzo Biochem by 25.5% during the first quarter. Nationwide Fund Advisors now owns 110,019 shares of the medical research company’s stock worth $921,000 after acquiring an additional 22,331 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of Enzo Biochem by 16.9% during the first quarter. Russell Investments Group Ltd. now owns 180,973 shares of the medical research company’s stock worth $1,515,000 after acquiring an additional 26,191 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Enzo Biochem by 47.9% during the first quarter. Wells Fargo & Company MN now owns 312,813 shares of the medical research company’s stock worth $2,618,000 after acquiring an additional 101,264 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of Enzo Biochem by 1.2% during the first quarter. Bank of New York Mellon Corp now owns 206,447 shares of the medical research company’s stock worth $1,728,000 after acquiring an additional 2,409 shares during the last quarter. Institutional investors own 62.70% of the company’s stock.

ENZ has been the subject of a number of recent research reports. BidaskClub downgraded Enzo Biochem from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. TheStreet downgraded Enzo Biochem from a “b” rating to a “c+” rating in a research report on Wednesday, September 27th. Finally, Zacks Investment Research downgraded Enzo Biochem from a “buy” rating to a “hold” rating in a research report on Tuesday, August 15th.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.watchlistnews.com/prudential-financial-inc-purchases-72720-shares-of-enzo-biochem-inc-enz/1611723.html.

Shares of Enzo Biochem, Inc. (NYSE:ENZ) opened at 10.36 on Friday. The company’s market cap is $482.23 million. Enzo Biochem, Inc. has a 52-week low of $4.88 and a 52-week high of $12.04. The stock’s 50 day moving average price is $10.88 and its 200-day moving average price is $10.07.

About Enzo Biochem

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Institutional Ownership by Quarter for Enzo Biochem (NYSE:ENZ)

Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.